# Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders

> **NCT02249676** · PHASE2 · COMPLETED · sponsor: **Tianjin Medical University General Hospital** · enrollment: 15 (actual)

## Conditions studied

- Devic's Syndrome
- Devic's Neuromyelitis Optica
- Devic Syndrome
- Devic's Disease
- Devic Disease

## Interventions

- **BIOLOGICAL:** Autologous mesenchymal stem cells

## Key facts

- **NCT ID:** NCT02249676
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-12-31
- **Final completion:** 2014-12-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249676, "Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02249676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*